Rosacea: Practical Guidance and Challenges for Clinical Management

References

• Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermato-Endocrinology. 2017;9(1):e1361574. doi:10.1080/19381980.2017.1361574
   PubMed Web of Science ®Google Scholar
• Gether L, Overgaard L, Egeberg A, Thyssen J. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282–289. doi:10.1111/bjd.16481
   PubMed Web of Science ®Google Scholar
• Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–341. doi:10.1016/j.jaad.2004.03.030
   PubMed Web of Science ®Google Scholar
• Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584–587. doi:10.1067/mjd.2002.120625
   PubMed Web of Science ®Google Scholar
• Barakji YA, Rønnstad ATM, Christensen MO, et al. Assessment of frequency of rosacea subtypes in patients with rosacea: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(6):617–625. doi:10.1001/jamadermatol.2022.0526
   PubMed Web of Science ®Google Scholar
• Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–155. doi:10.1016/j.jaad.2017.08.037
   PubMed Web of Science ®Google Scholar
• Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749–758. doi:10.1016/j.jaad.2014.08.028
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–980. doi:10.1038/nm1616
   PubMed Web of Science ®Google Scholar
• Schwab VD, Sulk M, Seeliger S, et al.. Neurovascular and Neuroimmune Aspects in the Pathophysiology of Rosacea. Elsevier; 2011:53–62.
   Google Scholar
• Sulk M, Seeliger S, Aubert J, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012;132(4):1253–1262. doi:10.1038/jid.2011.424
   PubMed Web of Science ®Google Scholar
• Seeliger S, Buddenkotte J, Schmidt-Choudhury A, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol. 2010;177(5):2563–2575. doi:10.2353/ajpath.2010.090941
   PubMed Web of Science ®Google Scholar
• Wladis EJ, Iglesias BV, Adam AP, Gosselin EJ. Molecular biologic assessment of cutaneous specimens of ocular rosacea. Ophthalmic Plast Reconstr Surg. 2012;28(4):246–250. doi:10.1097/IOP.0b013e31824dd9d4
   PubMed Web of Science ®Google Scholar
• McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63(1):33–39. doi:10.1016/j.jaad.2009.04.024
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen L-H, Y-s L, et al. Identification of novel candidate genes in rosacea by bioinformatic methods. Cytokine. 2021;141:155444. doi:10.1016/j.cyto.2021.155444
   PubMed Web of Science ®Google Scholar
• Forton FM, De Maertelaer V. Rosacea and demodicosis: little-known diagnostic signs and symptoms. Acta Derm Venereol. 2019;99(1):47–52. doi:10.2340/00015555-3041
   PubMed Web of Science ®Google Scholar
• Chang YS, Huang YC. Role of Demodex mite infestation in rosacea: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):441–447.e6. doi:10.1016/j.jaad.2017.03.040
   PubMed Web of Science ®Google Scholar
• Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24(2):126–135. doi:10.5021/ad.2012.24.2.126
   PubMed Web of Science ®Google Scholar
• Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69(6):1025–1032. doi:10.1016/j.jaad.2013.08.006
   PubMed Web of Science ®Google Scholar
• Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50(2):266–272. doi:10.1016/j.jaad.2003.05.005
   PubMed Web of Science ®Google Scholar
• Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update. J Am Acad Dermatol. 2018;78(4):786–792. e8. doi:10.1016/j.jaad.2017.09.016
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501–1510. doi:10.1016/j.jaad.2020.01.077
   PubMed Web of Science ®Google Scholar
• Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–764. doi:10.1016/j.cgh.2008.02.054
   PubMed Web of Science ®Google Scholar
• Cribier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol. 2013;27(11):1336–1343. doi:10.1111/jdv.12121
   PubMed Web of Science ®Google Scholar
• Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. 2000;42(3):468–472. doi:10.1016/S0190-9622(00)90220-2
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65–79. doi:10.1111/bjd.17590
   PubMed Web of Science ®Google Scholar
• Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142(8):1047–1052. doi:10.1001/archderm.142.8.1047
   PubMedGoogle Scholar
• Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–845. doi:10.1067/mjd.2003.308
   PubMed Web of Science ®Google Scholar
• Frampton JE, Wagstaff AJ. Azelaic acid 15% gel: in the treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5:57–64. doi:10.2165/00128071-200405010-00009
   PubMed Web of Science ®Google Scholar
• Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3–11.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother. 2008;9(15):2699–2706. doi:10.1517/14656566.9.15.2699
   PubMed Web of Science ®Google Scholar
• Williamson T, LaRose A, Cameron J, et al. Rosacea treatment satisfaction: matching adjusted indirect treatment comparison analysis of metronidazole gel or cream vs azelaic acid foam. J Drugs Dermatol. 2020;19(3):295–304. doi:10.36849/JDD.2020.3679
   PubMed Web of Science ®Google Scholar
• Dall’Oglio F, Tedeschi A, Lacarrubba F, et al. A novel azelaic acid formulation for the topical treatment of inflammatory rosacea: a multicentre, prospective clinical trial. J Cosmet Dermatol. 2021;20:28–31. doi:10.1111/jocd.14098
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z. Low-dose isotretinoin: an option for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016;136(6):1081–1083. doi:10.1016/j.jid.2016.03.003
   PubMed Web of Science ®Google Scholar
• MacGibeny MA, J-h J, Kong HH. Antibiotic stewardship in dermatology—reducing the risk of prolonged antimicrobial resistance in skin. JAMA Dermatol. 2022;158(9):989–991. doi:10.1001/jamadermatol.2022.3168
   PubMed Web of Science ®Google Scholar
• Hofer T. Continuous ‘microdose’ isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204–205. doi:10.1111/j.1365-2230.2004.01472.x
   PubMed Web of Science ®Google Scholar
• Jeon HW, Na EY, Yun SJ, Lee S-C, Lee J-B. Citron essential oils alleviate the mediators related to rosacea pathophysiology in epidermal keratinocytes. Ann Dermatol. 2018;30(6):653–661. doi:10.5021/ad.2018.30.6.653
   PubMed Web of Science ®Google Scholar
• Ebneyamin E, Mansouri P, Rajabi M, Qomi M, Asgharian R, Azizian Z. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: a double-blind, controlled clinical trial. J Cosmet Dermatol. 2020;19(6):1426–1431. doi:10.1111/jocd.13177
   PubMed Web of Science ®Google Scholar
• Breneman D, Stewart D, Hevia O, Hino P, Drake L. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61(1):44–47.
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Yamasaki K, Fujita T, Fujii C. Metronidazole gel (0.75%) in Japanese patients with rosacea: a randomized, vehicle-controlled, phase 3 study. J Dermatol. 2022;49(3):330–340. doi:10.1111/1346-8138.16254
   PubMed Web of Science ®Google Scholar
• Leyden JJ. Efficacy of a novel rosacea treatment system: an investigator-blind, randomized, parallel-group study. J Drugs Dermatol. 2011;10(10):1179–1185.
   PubMed Web of Science ®Google Scholar
• Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088–1097. doi:10.1016/j.jaad.2020.04.129
   PubMed Web of Science ®Google Scholar
• Bernstein EF, Schomacker K, Paranjape A, Jones CJ. Pulsed dye laser treatment of rosacea using a novel 15 mm diameter treatment beam. Lasers Surg Med. 2018;50(8):808–812. doi:10.1002/lsm.22819
   PubMed Web of Science ®Google Scholar
• Liu A, Moy RL, Ross EV, Hamzavi I, Ozog DM. Pulsed dye laser and pulsed dye laser–mediated photodynamic therapy in the treatment of dermatologic disorders. Dermatol Surg. 2012;38(3):351–366. doi:10.1111/j.1524-4725.2011.02293.x
   PubMed Web of Science ®Google Scholar
• Goldman MP, Eckhouse S. Photothermal sclerosis of leg veins. ESC medical systems, LTD photoderm VL Cooperative Study Group. Dermatol Surg. 1996;22(4):323–330. doi:10.1111/j.1524-4725.1996.tb00325.x
   PubMedGoogle Scholar
• Kim BY, Moon H-R, Ryu HJ. Comparative efficacy of short-pulsed intense pulsed light and pulsed dye laser to treat rosacea. J Cosmet Laser Ther. 2019;21(5):291–296. doi:10.1080/14764172.2018.1528371
   PubMed Web of Science ®Google Scholar
• Tirico M, Jensen D, Green C, Ross EV. Short pulse intense pulsed light versus pulsed dye laser for the treatment of facial redness. J Cosmet Laser Ther. 2020;22(2):60–64. doi:10.1080/14764172.2020.1717540
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Goldberg DJ, Dover JS, et al. Oxymetazoline and energy-based therapy in patients with Rosacea: evaluation of the safety and tolerability in an open-label, interventional study. Lasers Surg Med. 2021;53(1):55–65. doi:10.1002/lsm.23253
   PubMed Web of Science ®Google Scholar
• Suggs AK, Macri A, Richmond H, Munavalli G, Friedman PM. Treatment of erythematotelangiectatic rosacea with pulsed-dye laser and oxymetazoline 1.0% cream: a retrospective study. Lasers Surg Med. 2020;52(1):38–43. doi:10.1002/lsm.23176
   PubMed Web of Science ®Google Scholar
• Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17(1):97–105.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156–1163.
   PubMed Web of Science ®Google Scholar
• DuBois J, Dover JS, Jones TM, Weiss RA, Berk DR, Ahluwalia G. Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea. J Drugs Dermatol. 2018;17(3):308–316.
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Al‐Salman HN. Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol. 2006;45(7):857–861. doi:10.1111/j.1365-4632.2006.02944.x
   PubMed Web of Science ®Google Scholar
• Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. Int J Dermatol. 2012;51(4):459–462. doi:10.1111/j.1365-4632.2011.05353.x
   PubMed Web of Science ®Google Scholar
• Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020;33(6):e13976. doi:10.1111/dth.13976
   PubMed Web of Science ®Google Scholar
• Fowler JJ, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–656.
   PubMed Web of Science ®Google Scholar
• Jackson JM, Knuckles M, Minni JP, Johnson SM, Belasco KT. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015;529–538. doi:10.2147/CCID.S58920
   PubMedGoogle Scholar
• Jackson JM, Fowler J, Moore A, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol. 2014;13(6):699–704.
   PubMed Web of Science ®Google Scholar
• Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56–61.
   PubMed Web of Science ®Google Scholar
• Scharschmidt TC, Yost JM, Truong SV, Steinhoff M, Wang KC, Berger TG. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol. 2011;147(1):123–126. doi:10.1001/archdermatol.2010.413
   PubMedGoogle Scholar
• Alam M, Voravutinon N, Warycha M, et al. Comparative effectiveness of nonpurpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium:yttrium-aluminum-garnet laser for treatment of diffuse facial erythema: a double-blind randomized controlled trial. J Am Acad Dermatol. 2013;69(3):438–443. doi:10.1016/j.jaad.2013.04.015
   PubMed Web of Science ®Google Scholar
• Seo H-M, Kim J-I, Kim H-S, Choi Y-J, Kim W-S. Prospective comparison of dual wavelength long-pulsed 755-nm alexandrite/1064-nm neodymium:yttrium-aluminum-garnet laser versus 585-nm pulsed dye laser treatment for rosacea. Ann Dermatol. 2016;28(5):607–614. doi:10.5021/ad.2016.28.5.607
   PubMed Web of Science ®Google Scholar
• Lev-Tov H, Rill JS, Liu G, Kirby JS. Trends in utilization of topical medications for treatment of rosacea in the United States (2005–2014): a cohort analysis. J Am Acad Dermatol. 2019;80(4):1135–1137. doi:10.1016/j.jaad.2018.09.039
   PubMed Web of Science ®Google Scholar
• Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatolog Treat. 2019;30(2):158–169. doi:10.1080/09546634.2018.1473554
   PubMed Web of Science ®Google Scholar
• Sarac G. A comparison of the efficacy and tolerability of topical agents used in facial demodex treatment. J Cosmet Dermatol. 2019;18(6):1784–1787. doi:10.1111/jocd.12986
   PubMed Web of Science ®Google Scholar
• Kumar A, Chiou A, Shih Y, Li S, Chang A. An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183(5):942–943. doi:10.1111/bjd.19172
   PubMed Web of Science ®Google Scholar
• Dover JS, Arndt KA. New approaches to the treatment of vascular lesions. Lasers Surg Med. 2000;26(2):158–163. doi:10.1002/(sici)1096-9101(2000)26:2<158::aid-lsm6>3.0.co;2-o
   PubMed Web of Science ®Google Scholar
• Üstüner P, Balevi A, Özdemir M. The comparison of the efficacy and safety of q-switched potassium titanyl phosphate laser and long-pulsed neodymium-doped yttrium aluminum garnet laser in the treatment of erythematotelangiectatic and papulopustular rosacea. Turk J Dermatol. 2018;12(2):90–95. doi:10.4274/tdd.3535
   Google Scholar
• Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336–343. doi:10.1016/j.jaad.2019.05.063
   PubMed Web of Science ®Google Scholar
• Xu L, Yao B, Xu T, Huang H. Assessment of the efficacy and safety of 30% supramolecular salicylic acid peeling for papulopustular rosacea treatment. Indian J Dermatol. 2022;67(5):625. doi:10.4103/ijd.ijd_353_21
   PubMed Web of Science ®Google Scholar
• Wang L, Li XH, Wen X, et al. Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels. Exp Ther Med. 2020;20(2):1048–1052. doi:10.3892/etm.2020.8740
   PubMed Web of Science ®Google Scholar
• Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2013;68(5):875–876. doi:10.1016/j.jaad.2012.11.038
   PubMed Web of Science ®Google Scholar
• Drago F, De Col E, Agnoletti AF, et al. The role of small intestinal bacterial overgrowth in rosacea: a 3-year follow-up. J Am Acad Dermatol. 2016;75(3):e113–e115. doi:10.1016/j.jaad.2016.01.059
   PubMed Web of Science ®Google Scholar
• Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatological Sci. 2019;93(1):58–64. doi:10.1016/j.jdermsci.2018.12.004
   PubMed Web of Science ®Google Scholar
• Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015;230(4):299–301. doi:10.1159/000368773
   PubMed Web of Science ®Google Scholar
• Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641–645.
   PubMedGoogle Scholar
• Reitamo S, Remitz A, Kyllönen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381–388. doi:10.2165/00128071-200203060-00002
   PubMedGoogle Scholar
• Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021;84(2):543–545. doi:10.1016/j.jaad.2020.05.050
   PubMed Web of Science ®Google Scholar
• Oussedik E, Bourcier M, Tan J. Psychosocial burden and other impacts of rosacea on patients’ quality of life. Dermatol Clin. 2018;36(2):103–113. doi:10.1016/j.det.2017.11.005
   PubMed Web of Science ®Google Scholar
• Schlesinger TE, Powell CR. Efficacy and tolerability of low molecular weight hyaluronic acid sodium salt 0.2% cream in rosacea. J Drugs Dermatol. 2013;12(6):664–667.
   PubMed Web of Science ®Google Scholar
• Proietti I, Skroza N, Potenza C. Improving skin quality in patients with dermatologic conditions using the hyaluronic acid filler VYC-12. G Ital Dermatol Venereol. 2020;2020:06453.
   Google Scholar
• Gariboldi S, Palazzo M, Zanobbio L, et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. J Immunol. 2008;181(3):2103–2110. doi:10.4049/jimmunol.181.3.2103
   PubMed Web of Science ®Google Scholar
• Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13(6):685–688.
   PubMed Web of Science ®Google Scholar
• Abramovits W, Jessu R, Vincent KD, Gupta AK. Epsolay™ (Microencapsulated Benzoyl Peroxide 5%) cream for the topical treatment of rosacea. Skinmed. 2023;21(2):110–111.
   PubMedGoogle Scholar
• Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245. doi:10.1016/j.pharmthera.2014.03.003
   PubMed Web of Science ®Google Scholar
• Modi S, Harting M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol. 2008;7(9):898–899.
   PubMedGoogle Scholar
• Korting H, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23(8):876–882. doi:10.1111/j.1468-3083.2009.03167.x
   PubMed Web of Science ®Google Scholar
• Kim J-H, Oh YS, Choi EH. Oral azithromycin for treatment of intractable rosacea. J Korean Med Sci. 2011;26(5):694–696. doi:10.3346/jkms.2011.26.5.694
   PubMed Web of Science ®Google Scholar
• Bakar Ö, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43(2):151–154. doi:10.1111/j.1365-4632.2004.01958.x
   PubMed Web of Science ®Google Scholar
• Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284–288. doi:10.1111/j.1365-4632.2008.03445.x
   PubMed Web of Science ®Google Scholar
• Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36(12):942–946. doi:10.1046/j.1365-4362.1997.00301.x
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015(4):Cd003262. doi:10.1002/14651858.CD003262.pub5
   PubMedGoogle Scholar
• Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316–323.
   PubMed Web of Science ®Google Scholar
• Taieb A, Ortonne J, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0· 75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103–1110. doi:10.1111/bjd.13408
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: a systematic review and meta-analysis. Dermatol Ther. 2020;33(1):e13203. doi:10.1111/dth.13203
   PubMed Web of Science ®Google Scholar
• Kwon HH, Jung JY, Lee WY, Bae Y, Park GH. Combined treatment of recalcitrant papulopustular rosacea involving pulsed dye laser and fractional microneedling radiofrequency with low-dose isotretinoin. J Cosmet Dermatol. 2020;19(1):105–111. doi:10.1111/jocd.12982
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Brantman S, Baldwin H. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily. Dermatol Ther. 2022;35(1):e15180. doi:10.1111/dth.15180
   PubMed Web of Science ®Google Scholar
• Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129–140. doi:10.2147/ccid.s4296
   PubMedGoogle Scholar
• Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75(4 Suppl):6–11.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8(7):664–668.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791–802. doi:10.1016/j.jaad.2006.11.021
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1(1):20.
   PubMedGoogle Scholar
• van der Linden MMD, van Ratingen AR, van Rappard DC, Nieuwenburg SA, Spuls PI. DOMINO, doxycycline 40 mg vs minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176(6):1465–1474. doi:10.1111/bjd.15155
   PubMed Web of Science ®Google Scholar
• Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. Br J Dermatol. 2009;161(4):814–818. doi:10.1111/j.1365-2133.2009.09317.x
   PubMed Web of Science ®Google Scholar
• Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea – doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8(7):505–514. doi:10.1111/j.1610-0387.2010.07345.x
   PubMed Web of Science ®Google Scholar
• Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94(2):200–206. doi:10.1111/j.1444-0938.2010.00540.x
   PubMed Web of Science ®Google Scholar
• Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Article. Cornea. 2013;32(1):44–53. doi:10.1097/ICO.0b013e318254205f
   PubMed Web of Science ®Google Scholar
• Yildiz E, Yenerel NM, Turan-Yardimci A, Erkan M, Gunes P. Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis. Article. J Ocul Pharmacol Ther. 2018;34(4):365–372. doi:10.1089/jop.2017.0095
   PubMed Web of Science ®Google Scholar
• Zandian M, Rahimian N, Soheilifar S. Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis. Article. Int J Ophthalmol. 2016;9(7):1016–1019. doi:10.18240/ijo.2016.07.14
   PubMed Web of Science ®Google Scholar
• Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9(11):904–907. doi:10.1111/j.1610-0387.2011.07723.x
   PubMed Web of Science ®Google Scholar
• Guarrera M, Parodi A, Cipriani C, Divano C, Rebora A. Flushing in rosacea: a possible mechanism. Arch Dermatol Res. 1982;272(3–4):311–316. doi:10.1007/bf00509061
   PubMed Web of Science ®Google Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;9:Cd004923. doi:10.1002/14651858.CD004923.pub2
   PubMed Web of Science ®Google Scholar
• Sahni DR, Feldman SR, Taylor SL. Ivermectin 1% (CD5024) for the treatment of rosacea. Expert Opin Pharmacother. 2018;19(5):511–516. doi:10.1080/14656566.2018.1447562
   PubMed Web of Science ®Google Scholar
• Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–1450. doi:10.1001/archderm.139.11.1444
   PubMedGoogle Scholar
• Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol. 2006;5(2 Suppl):6–8.
   PubMedGoogle Scholar
• Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791–797. doi:10.1016/j.jaad.2005.04.069
   PubMed Web of Science ®Google Scholar
• Engin B, Özkoca D, Kutlubay Z, Serdaroğlu S. Conventional and novel treatment modalities in rosacea. Clin Cosmet Investig Dermatol. 2020;13:179–186. doi:10.2147/ccid.S194074
   PubMed Web of Science ®Google Scholar
• Schweinzer K, Kofler L, Spott C, et al. Surgical treatment of rhinophyma: experience from a German cohort of 70 patients. Eur J Dermatol. 2017;27:281–285. doi:10.1684/ejd.2017.2987
   PubMed Web of Science ®Google Scholar
• Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004;15(6):499–502. doi:10.1097/01.icu.0000143683.14738.76
   PubMedGoogle Scholar
• Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis. 2001;68(2):112–114.
   PubMed Web of Science ®Google Scholar
• Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology. 1996;103(11):1880–1883. doi:10.1016/s0161-6420(96)30412-0
   PubMed Web of Science ®Google Scholar
• Lee GL, Zirwas MJ. Granulomatous rosacea and periorificial dermatitis: controversies and review of management and treatment. Dermatol Clin. 2015;33(3):447–455. doi:10.1016/j.det.2015.03.009
   PubMed Web of Science ®Google Scholar
• Walsh RK, Endicott AA, Shinkai K. Diagnosis and treatment of rosacea fulminans: a comprehensive review. Am J Clin Dermatol. 2018;19:79–86. doi:10.1007/s40257-017-0310-0
   PubMed Web of Science ®Google Scholar
• Wollina U, Jelin AC, Thiet M-P. Recent advances in the understanding and management of rosacea. F1000prime Rep. 2014;6:6. doi:10.12703/P6-6
   PubMedGoogle Scholar
• Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Biochem Pharmacol. 1986;35(1):53–58. doi:10.1016/0006-2952(86)90554-x
   PubMed Web of Science ®Google Scholar
• Edwards DI. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993;31(1):9–20. doi:10.1093/jac/31.1.9
   PubMed Web of Science ®Google Scholar
• Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol. 1983;108(3):327–332. doi:10.1111/j.1365-2133.1983.tb03972.x
   PubMed Web of Science ®Google Scholar
• Sauder D, Miller R, Gratton D, Danby W, Griffiths C, Phillips S. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8(2):79–85. doi:10.3109/09546639709160276
   Web of Science ®Google Scholar
• Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75(6):357–363.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:651–659. doi:10.1007/s12325-009-0037-2
   PubMed Web of Science ®Google Scholar
• Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8(3):544–549. doi:10.3980/j.issn.2222-3959.2015.03.19
   PubMed Web of Science ®Google Scholar
• Marchitto MC, Chien AL. Mast cell stabilizers in the treatment of rosacea: a review of existing and emerging therapies. Dermatol Ther. 2021;11(5):1541–1549. doi:10.1007/s13555-021-00597-7
   Web of Science ®Google Scholar
• Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharmacal Res. 2013;36:237–251. doi:10.1007/s12272-013-0057-y
   PubMed Web of Science ®Google Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–113. doi:10.1016/j.coph.2005.11.003
   PubMed Web of Science ®Google Scholar
• Parkins G, Maan A, Dawn G. Neurogenic rosacea: an uncommon and poorly recognized entity?. Clin Exp Dermatol. 2015;40(8):930–931. doi:10.1111/ced.12630
   PubMed Web of Science ®Google Scholar
• Hayran Y, Şen O, Fırat Oğuz E, et al. Serum IL-17 levels in patients with rosacea. J Cosmet Dermatol. 2022;21(3):1147–1153. doi:10.1111/jocd.14169
   PubMed Web of Science ®Google Scholar
• Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea treatment: review and update. Dermatol Ther. 2021;11:13–24. doi:10.1007/s13555-020-00461-0
   PubMed Web of Science ®Google Scholar
• Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16(9):909–916.
   PubMed Web of Science ®Google Scholar
• Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient’s quality of life. Am Health Drug Benefits. 2013;6(6):348–354.
   PubMedGoogle Scholar
• Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther. 2019;9:725–734. doi:10.1007/s13555-019-00322-5
   Web of Science ®Google Scholar